Loading...
Market
What will be Seaport Therapeutics' valuation by the end of 2025?
3
Resolution / Starting Odds
Below $1 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
Above $3 billion • 25%
Financial reports or valuation announcements by Seaport Therapeutics
Story
Seaport Therapeutics Secures $225M in Oversubscribed Series B Round Led by General Atlantic
Oct 21, 2024, 06:14 AM
Seaport Therapeutics, a company founded by PureTech, has successfully closed a $225 million oversubscribed Series B financing round. The financing round was led by General Atlantic and includes an impressive group of investors. The funds will be used to advance Seaport Therapeutics' efforts in developing better medicines for depression, anxiety, and other neuropsychiatric disorders. This significant investment comes as the company aims to embrace what it describes as the 'golden age of neuroscience.' SeaportTx announced the news.
View original story
Similar markets
Less than $250M • 33%
$250M to $500M • 33%
More than $500M • 34%
Under $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Over $2 billion • 25%
Above $10 • 25%
$5 - $10 • 25%
$1 - $5 • 25%
Below $1 • 25%
Below $15 billion • 25%
$15-$19.99 billion • 25%
$20-$24.99 billion • 25%
$25 billion or above • 25%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $5 billion • 25%
More than $5 billion • 25%
Less than $1B • 25%
$1B to $2B • 25%
$2B to $3B • 25%
More than $3B • 25%
Above $10 • 25%
$8-$10 • 25%
$6-$8 • 25%
Below $6 • 25%
Less than $200M • 25%
$200M - $400M • 25%
$400M - $600M • 25%
More than $600M • 25%
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%